RZLT
NASDAQ · Biotechnology
Rezolute Inc
$3.84
-0.11 (-2.78%)
Open$3.95
Previous Close$3.95
Day High$3.95
Day Low$3.67
52W High$11.46
52W Low$1.07
Volume—
Avg Volume1.35M
Market Cap371.69M
P/E Ratio—
EPS$-0.81
SectorBiotechnology
Analyst Ratings
Strong Buy
16 analysts
Price Target
+351.8% upside
Current
$3.84
$3.84
Target
$17.35
$17.35
$11.58
$17.35 avg
$20.59
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 45.23M | 44.79M | 46.31M |
| Net Income | 4.09M | 3.84M | 4.53M |
| Profit Margin | 9.0% | 8.6% | 9.8% |
| EBITDA | 6.09M | 5.25M | 5.80M |
| Free Cash Flow | 2.47M | 3.54M | 3.43M |
| Rev Growth | +6.6% | +21.1% | +6.0% |
| Debt/Equity | 0.15 | 0.18 | 0.13 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $265.21 | +0.28% | 74.0 | 466.74B |
| AMGN | Amgen Inc | $410.24 | +4.34% | 23.7 | 207.25B |
| GILD | Gilead Sciences Inc | $152.67 | +1.40% | — | 187.10B |
| VRTX | Vertex Pharmaceuticals Inc | $514.99 | +0.84% | 29.7 | 130.64B |
| REGN | Regeneron Pharmaceuticals | $803.90 | +0.72% | 18.6 | 80.58B |
| ALNY | Alnylam Pharmaceuticals Inc | $251.65 | +3.00% | 40.0 | 32.33B |